Children and Youth Who Use Cannabis for Pain Relief: Benefits, Risks, and Perceptions

References

• Currie C, Zanotti C, Morgan A, et al. Social Determinants of Health and Well-Being Among Young People. Health Behaviour in School-Aged Children (HBSC) Study: International Report from the 2009/2010 Survey. World Health Organization; 2012.
   Google Scholar
• Johnston L, Miech R, O’Malley PM, Bachman J, Schulenberg J, Patrick M. Monitoring the Future National Survey Results on Drug Use: 1975-2017: Overview, Key Findings on Adolescent Drug Use. Michigan: The University of Michigan Institute for Social Research; 2018.
   Google Scholar
• Miech R, Johnston L, O’Malley PM. Prevalence and attitudes regarding marijuana use among adolescents over the past decade. Pediatrics. 2017;140(6):e20170982. doi:10.1542/peds.2017-0982
   PubMed Web of Science ®Google Scholar
• State Medical Marijuana Laws. National conference of state legislatures; 2020. Available from: https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx.
   Google Scholar
• Health Canada. Information for Health Care Professionals: cannabis and the Cannabinoids. Government of Canada; 2018. Available from: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids.html#a5.0.
   Google Scholar
• Katona I, Rancz EA, Acsády L, et al. Distribution of CB1 cannabinoid receptors in the amygdala and their role in the control of GABAergic transmission. J Neurosci. 2001;21(23):9506–9518. doi:10.1523/JNEUROSCI.21-23-09506.2001
   Web of Science ®Google Scholar
• Lu H-C, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516–525. doi:10.1016/j.biopsych.2015.07.028
   PubMed Web of Science ®Google Scholar
• Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142(2):278–287. doi:10.1006/taap.1996.8034
   PubMed Web of Science ®Google Scholar
• Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A. 2008;105(7):2699–2704. doi:10.1073/pnas.0711278105
   PubMed Web of Science ®Google Scholar
• Fride E, Foox A, Rosenberg E, et al. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a “CB3” receptor. Eur J Pharmacol. 2003;461(1):27–34. doi:10.1016/s0014-2999(03)01295-0
   PubMed Web of Science ®Google Scholar
• Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199–215. doi:10.1038/sj.bjp.0707442
   PubMed Web of Science ®Google Scholar
• Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol. 2007;150(5):613–623. doi:10.1038/sj.bjp.0707133
   PubMed Web of Science ®Google Scholar
• Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther. 2017;175:133–150. doi:10.1016/j.pharmthera.2017.02.041
   PubMed Web of Science ®Google Scholar
• FDA Information. Marinol (Dronabinol). High Point, North Carolina: Solvay Pharmaceuticals; 2004. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf.
   Google Scholar
• FDA Information. Cesamet (Nabilone). Costa Mesa, California: Valeant Pharmaceuticals International; 2006. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf.
   Google Scholar
• Baron EP. Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science. Headache. 2018;58(7):1139–1186. doi:10.1111/head.13345
   PubMed Web of Science ®Google Scholar
• Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344–1364. doi:10.1111/j.1476-5381.2011.01238.x
   PubMed Web of Science ®Google Scholar
• Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358
   PubMed Web of Science ®Google Scholar
• Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3:CD012182. doi:10.1002/14651858.CD012182.pub2
   PubMed Web of Science ®Google Scholar
• Andreae MH, Carter GM, Shaparin N, et al. Inhaled cannabis for chronic neuropathic pain: a meta-analysis of individual patient data. J Pain. 2015;16(12):1221–1232. doi:10.1016/j.jpain.2015.07.009
   PubMed Web of Science ®Google Scholar
• Boyd CJ, Veliz PT, McCabe SE. Adolescents’ use of medical marijuana: a secondary analysis of monitoring the future data. J Adolesc Health. 2015;57(2):241–244. doi:10.1016/j.jadohealth.2015.04.008
   PubMed Web of Science ®Google Scholar
• Medical marijuana statistics and data. Colorado Department of Public Health and Environment; February 2020. Available from: https://www.colorado.gov/pacific/cdphe/medical-marijuana-statistics-and-data. Accessed April 7, 2020.
   Google Scholar
• Washington State Department of Health. Medical marijuana data and statistics; April 25, 2019. Available from: https://www.doh.wa.gov/YouandYourFamily/Marijuana/MedicalMarijuana/AuthorizationDatabase/DataandStatistics. Accessed June 15, 2019..
   Google Scholar
• Tucker JS, Rodriguez A, Pedersen ER, Seelam R, Shih RA, D’Amico EJ. Greater risk for frequent marijuana use and problems among young adult marijuana users with a medical marijuana card. Drug Alcohol Depend. 2019;194:178–183. doi:10.1016/j.drugalcdep.2018.09.028
   PubMed Web of Science ®Google Scholar
• Lankenau SE, Ataiants J, Mohanty S, Schrager S, Iverson E, Wong CF. Health conditions and motivations for marijuana use among young adult medical marijuana patients and non-patient marijuana users. Drug Alcohol Rev. 2018;37(2):237–246. doi:10.1111/dar.12534
   PubMed Web of Science ®Google Scholar
• Fedorova EV, Schrager SM, Robinson LF, et al. Illicit drug use and prescription drug misuse among young adult medical cannabis patients and non-patient users in Los Angeles. Drug Alcohol Depend. 2019;198:21–27. doi:10.1016/j.drugalcdep.2019.01.026
   PubMed Web of Science ®Google Scholar
• Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: results from a national sample. Addict Behav. 2016;61:99–103. doi:10.1016/j.addbeh.2016.05.015
   PubMed Web of Science ®Google Scholar
• Wall MM, Liu J, Hasin DS, Blanco C, Olfson M. Use of marijuana exclusively for medical purposes. Drug Alcohol Depend. 2019;195:13–15. doi:10.1016/j.drugalcdep.2018.11.009
   PubMed Web of Science ®Google Scholar
• Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9. doi:10.1186/s12954-019-0278-6
   PubMed Web of Science ®Google Scholar
• Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6(1):35. doi:10.1186/1477-7517-6-35
   PubMed Web of Science ®Google Scholar
• Bachhuber MA, Saloner B, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med. 2014;174(10):1668–1673. doi:10.1001/jamainternmed.2014.4005
   PubMed Web of Science ®Google Scholar
• Osborn LA, Lauritsen KJ, Cross N, et al. Self-medication of somatic and psychiatric conditions using botanical marijuana. J Psychoactive Drugs. 2015;47(5):345–350. doi:10.1080/02791072.2015.1096433
   PubMed Web of Science ®Google Scholar
• Bonn‐Miller MO, Vujanovic AA, Feldner MT, Bernstein A, Zvolensky MJ. Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users. J Trauma Stress. 2007;20(4):577–586. doi:10.1002/jts.20243
   PubMed Web of Science ®Google Scholar
• Rudich Z, Stinson J, Jeavons M, Brown SC. Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents. Pain Res Manag. 2003;8(4):221–224. doi:10.1155/2003/675976
   Google Scholar
• Libzon S, Schleider -LB-L, Saban N, et al. Medical cannabis for pediatric moderate to severe complex motor disorders. J Child Neurol. 2018;33(9):565–571. doi:10.1177/0883073818773028
   Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice, Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017. Available from: http://www.ncbi.nlm.nih.gov/books/NBK423845/.Accessed April 9, 2020.
   Google Scholar
• Wong SS, Wilens TE. Medical cannabinoids in children and adolescents: a systematic review. Pediatrics. 2017;140(5). doi:10.1542/peds.2017-1818
   Web of Science ®Google Scholar
• Schimrigk S, Marziniak M, Neubauer C, Kugler EM, Werner G, Abramov-Sommariva D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5–6):320–329. doi:10.1159/000481089
   PubMed Web of Science ®Google Scholar
• Hoggart B, Ratcliffe S, Ehler E, et al. A multicentre, open-label, follow-on study to assess the long-term maintenance of effect, tolerance and safety of THC/CBD oromucosal spray in the management of neuropathic pain. J Neurol. 2015;262(1):27–40. doi:10.1007/s00415-014-7502-9
   Web of Science ®Google Scholar
• Scott JC, Slomiak ST, Jones JD, Rosen AFG, Moore TM, Gur RC. Association of cannabis with cognitive functioning in adolescents and young adults: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75(6):585–595. doi:10.1001/jamapsychiatry.2018.0335
   PubMed Web of Science ®Google Scholar
• Robertson RD, Mainegra Hing M, Pashley CR, Brown SW, Vanlaar WGM. Prevalence and trends of drugged driving in Canada. Accid Anal Prev. 2017;99(Pt A):236–241. doi:10.1016/j.aap.2016.12.008
   PubMed Web of Science ®Google Scholar
• Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies. Accid Anal Prev. 2013;60:254–267. doi:10.1016/j.aap.2012.06.017
   PubMed Web of Science ®Google Scholar
• Rogeberg O, Elvik R. The effects of cannabis intoxication on motor vehicle collision revisited and revised. Addict Abingdon Engl. 2016;111(8):1348–1359. doi:10.1111/add.13347
   PubMed Web of Science ®Google Scholar
• Asbridge M, Hayden JA, Cartwright JL. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ. 2012;344:e536. doi:10.1136/bmj.e536
   PubMed Web of Science ®Google Scholar
• Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G. Marijuana use and motor vehicle crashes. Epidemiol Rev. 2012;34(1):65–72. doi:10.1093/epirev/mxr017
   PubMed Web of Science ®Google Scholar
• Lenné MG, Dietze PM, Triggs TJ, Walmsley S, Murphy B, Redman JR. The effects of cannabis and alcohol on simulated arterial driving: influences of driving experience and task demand. Accid Anal Prev. 2010;42(3):859–866. doi:10.1016/j.aap.2009.04.021
   PubMed Web of Science ®Google Scholar
• Gobbi G, Atkin T, Zytynski T, et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a systematic review and meta-analysis. JAMA Psychiatry. 2019. doi:10.1001/jamapsychiatry.2018.4500
   Web of Science ®Google Scholar
• Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to Pot – A review of the association between cannabis and psychosis. Front Psychiatry. 2014;5. doi:10.3389/fpsyt.2014.00054
   Web of Science ®Google Scholar
• Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E. Meta-analysis of the association between the level of cannabis use and risk of Psychosis. Schizophr Bull. 2016;42(5):1262–1269. doi:10.1093/schbul/sbw003
   PubMed Web of Science ®Google Scholar
• Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry J Ment Sci. 2009;195(6):488–491. doi:10.1192/bjp.bp.109.064220
   PubMed Web of Science ®Google Scholar
• Miettunen J, Törmänen S, Murray GK, et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry J Ment Sci. 2008;192(6):470–471. doi:10.1192/bjp.bp.107.045740
   PubMed Web of Science ®Google Scholar
• Manseau MW, Goff DC. Cannabinoids and schizophrenia: risks and therapeutic potential. Neurotherapeutics. 2015;12(4):816–824. doi:10.1007/s13311-015-0382-6
   PubMed Web of Science ®Google Scholar
• Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1–25. doi:10.1016/j.neubiorev.2018.07.014
   PubMed Web of Science ®Google Scholar
• Lopez-Quintero C, Pérez de Los Cobos J, Hasin DS, et al. Probability and predictors of transition from first use to dependence on nicotine, alcohol, cannabis, and cocaine: results of the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2011;115(1–2):120–130. doi:10.1016/j.drugalcdep.2010.11.004
   PubMed Web of Science ®Google Scholar
• Volkow ND, Baler RD, Compton WM, Weiss SRB. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–2227. doi:10.1056/NEJMra1402309
   PubMed Web of Science ®Google Scholar
• Lynskey MT, Heath AC, Bucholz KK, et al. Escalation of drug use in early-onset cannabis users vs co-twin controls. JAMA. 2003;289(4):427–433. doi:10.1001/jama.289.4.427
   PubMed Web of Science ®Google Scholar
• Reddon H, DeBeck K, Socias ME, et al. Cannabis use is associated with lower rates of initiation of injection drug use among street-involved youth: a longitudinal analysis. Drug Alcohol Rev. 2018;37(3):421–428. doi:10.1111/dar.12667
   PubMed Web of Science ®Google Scholar
• Shover CL, Davis CS, Gordon SC, Humphreys K. Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proc Natl Acad Sci. 2019;116(26):12624–12626. doi:10.1073/pnas.1903434116
   PubMed Web of Science ®Google Scholar
• McBrien H, Luo C, Sanger N, et al. Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. CMAJ Open. 2019;7(4):E665–E673. doi:10.9778/cmajo.20190026
   PubMedGoogle Scholar
• Qato DM, Alexander GC, Guadamuz JS, Lindau ST. Prescription medication use among children and adolescents in the United States. Pediatrics. 2018;142(3):e20181042. doi:10.1542/peds.2018-1042
   Web of Science ®Google Scholar
• Brown JD. Potential adverse drug events with tetrahydrocannabinol (THC) due to drug–drug interactions. J Clin Med. 2020;9(4):919. doi:10.3390/jcm9040919
   Web of Science ®Google Scholar
• Bottorff JL, Johnson JL, Moffat BM, Mulvogue T. Relief-oriented use of marijuana by teens. Subst Abuse Treat Prev Policy. 2009;4(1):7. doi:10.1186/1747-597X-4-7
   PubMed Web of Science ®Google Scholar
• McKiernan A, Fleming K. Canadian Youth Perceptions on Cannabis. Ottawa, Ontario: Canadian Centre on Substance Abuse; 2017.
   Google Scholar
• Ananth P, Ma C, Al-Sayegh H, et al. Provider perspectives on use of medical marijuana in children with cancer. Pediatrics. 2018;141(1):e20170559. doi:10.1542/peds.2017-0559
   PubMed Web of Science ®Google Scholar
• Tibbo P, Crocker CE, Lam RW, Meyer J, Sareen J, Aitchison K. Implications of Cannabis Legalization on Youth and Young Adults. Canadian Psychiatric Association; 2017.
   Google Scholar
• Ammerman S, Ryan S, Adelman WP, Committee on Substance Abuse, the Committee on Adolescence. The impact of marijuana policies on youth: clinical, research, and legal update. Pediatrics. 2015;135(3):e769–e785. doi:10.1542/peds.2014-4147
   PubMed Web of Science ®Google Scholar
• Grant CN, Richard EB, Canadian Paediatric Society. Cannabis and Canada’s children and youth. Paediatr Child Health. 2017;22(2):98–102. doi:10.1093/pch/pxx017
   Web of Science ®Google Scholar
• Rieder MJ. Is the medical use of cannabis a therapeutic option for children? Paediatr Child Health. 2016;21(1):31–34. doi:10.1093/pch/21.1.31
   Web of Science ®Google Scholar
• Martinasek MP, McGrogan JB, Maysonet A. A systematic review of the respiratory effects of inhalational marijuana. Respir Care. 2016;61(11):1543–1551. doi:10.4187/respcare.04846
   PubMed Web of Science ®Google Scholar
• Dalton VS, Long LE, Weickert CS, Zavitsanou K. Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology. 2011;36(8):1620–1630. doi:10.1038/npp.2011.43
   PubMed Web of Science ®Google Scholar
• Benyamina A, Karila L, Lafaye G, Blecha L. Genetic influences in cannabis use disorder and psychosis: dopamine and beyond. Curr Pharm Des. 2016;22(42):6392–6396. doi:10.2174/1381612822666160831095707
   Web of Science ®Google Scholar
• Vergara D, Bidwell LC, Gaudino R, et al. Compromised external validity: federally produced cannabis does not reflect legal markets. Sci Rep. 2017;7:46528. doi:10.1038/srep46528
   PubMed Web of Science ®Google Scholar